Medical network on September 22 - kang CMH data according to the testing data, the respiratory system in our country medicine scale up to 137.2 billion yuan, including inhalation preparation market rising, 2016 drug market size is 9.3 billion yuan, increased by 22.4% year-on-year in 2015. With a view of the products and manufacturers of the market, the market concentration is high, and the market share of TOP5 enterprises is 98.3% of the market...
With the high-speed development of economy and the accelerating process of industrialization, air pollution and people lifestyle changes, the respiratory system diseases such as asthma and copd prevalence showed a trend of rapid rise, China has an estimated 70 million patients with asthma and copd patients.
Inhaled preparations use a projectile, compressed air or special device to disperse the drug into a mist, forming a drug aerosol that causes the drug to reach the site directly. Compared with oral drugs, inhalation preparations first effect, can avoid the liver with inhaled drug stimulation in patients with small, easy to use, good adaptability, small side effects, suitable for long-term treatment, etc, the world health organization (who) has recommended it as the first choice for respiratory diseases such as asthma and chronic obstructie pulmonary therapy, has a broad market prospects for development in our country.
Nearly a billion market size, annual growth of 22.4%
According to the China kang CMH monitoring data, in 2016, China's respiratory system reached 137.2 billion yuan, with 69 percent taking oral medication and 20 percent of injections, compared with 7 percent for inhaled drugs. In recent years, the market for inhaled drug inhalation has been on the rise, and the market medicine volume in 2016 was 9.3 billion yuan, up by 22.4% year on year.
Of the four categories, the corticosteroid hormone is half of the mountain
Currently inhalation agents mainly include corticosteroid hormone, beta-epinephrine receptor agonist, M cholinergic receptor antagonist and compound preparation. The proportion of corticosteroid hormone in inhalation was increased year by year, and 47.8% in 2016. The second was beta agonist/cortical hormone, which accounted for 26.8%.
Inhalation of glucocorticoid hormones for bronchial asthma medication treatment for a long time, can avoid systemic glucocorticoids cause various adverse reactions, the main clinical mainly USES budesonide, fluticasone and beclomethasone dipropionate, etc.; Beta-epinephrine receptor agonists mainly include formoterol, albuterol, terbutaline, etc. Anticholinergic drugs play an important role in the treatment of asthma and COPD. The main cultivars are isopropyl bromide and thiotonium bromide. Beta agonist/corticosteroid is the most clinical use of compound dosage forms, mainly for the sariatatasson of GSK and the budi fumodero of astrazeneca.
The market concentration is high, the TOP5 variety accounts for 80%
In 2016, the total market share of TOP5 varieties of inhaled preparations was 84.3%, and the market concentration was high. From a single variety, budesonide is one of the largest inhalation preparation varieties, sales market share accounted for 45%, on the market at present with the inhaled suspension liquid, powder inhaler, aerosol 3 kinds, among them the inhaled mixed suspension largest and for astrazeneca exclusive sales. Glucocorticoid is the most effective anti-inflammatory drug, and long-term continuous inhalation of hormone drugs is one of the treatment methods for recurrent asthma attacks.
For patients with unilateral less faorable outcomes after treatment of compound preparations salmeterol assigned and budesonide f ROM for mott as long-term asthma control drug use, development is rapid in recent years.
Thiamethoxam bromide is the first kind of choline long-acting antibacterial drugs, in the maintenance treatment of copd plays an important role, in domestic market, in 2006, the two main domestic manufacturers are now a boehringer ingelheim and super shine.
Inhaled preparation market share TOP5 variety
Foreign companies account for over 90 percent of the market
In 2016, the total market share of TOP5 manufacturers was 98.3%, and the market concentration was very high. The top three companies are all foreign-invested enterprises, accounting for 95% of the shares, including astrazeneca (57.1%), glaxosmithkline (24.4%) and boehringer ingohan (13.6%). The next two are domestic companies such as zhengzheng tianqing (2.6%) and lunan pharmaceutical (0.5%), and the market share is small (3.1%).
From each manufacturer in inhalation preparation share proportion changes in recent years, astrazeneca's proportion in inhalation preparation market gradually expanded, and inhaled a cloth to Ned suspension liquid, Mick shu) for its contributed seventy percent of its sales, belongs to the annual sales of more than 1 billion varieties; The second is the bimonde formottroo powder inhaler (the letter must be guaranteed); In addition, it also owns the varieties of inhaled preparations, such as terbutalin and formottro.
In second place glaxosmithkline in inhalation preparations in recent years, market share accounted for in the fall, the main varieties of inhalation preparation for salmeterol assigned (nimesulide) composite), with annual sales of more than 1 billion varieties, sales and billions of salbutamol (torin), fluticasone (auxiliary shu ketone), etc.
The main cultivars of boehringer ingerhan are isopropyl bromide (aiquan), thiotripium bromide (silihua), and pieter, with annual sales of more than 100 million.
The market share of the two domestic manufacturers is relatively small, and the main products of zhengda tianqing are the varieties of titronium bromide, with annual sales of over 100 million and increasing year by year. And ruonan pharmaceuticals is the budesonide variety.
In general, the production technology of inhaled preparations is high, and domestic enterprises are slow to start. At present, foreign-funded enterprises have a big advantage in the market of most inhaled pharmaceutical products.
Inhalation preparation TOP5 manufacturer competition pattern
|
